Core Viewpoint - The launch of China's first domestically produced nine-valent HPV vaccine marks a significant advancement in cervical cancer prevention for women aged 9 to 45 in Shanghai, providing a new option for vaccination [1][3]. Group 1: Vaccine Details - The nine-valent HPV vaccine is priced at 499 yuan per dose, totaling 506.5 yuan including service fees in Shanghai [1]. - The vaccination schedule for women aged 9 to 17 consists of two doses administered at 0 and 6 months, with a total cost of approximately 1013 yuan; for women aged 18 to 45, a three-dose schedule is followed at 0, 1, and 6 months, costing around 1519.5 yuan [1]. - The vaccine has been fully launched in Shanghai, with initial doses being distributed to community health service centers, and citizens can make appointments through a health app or by contacting local centers [1]. Group 2: Clinical Research and Safety - The vaccine underwent 18 years of research, involving over one million independent tests and multiple clinical studies, with about 11,000 healthy female volunteers participating in trials since 2019 [4][7]. - The adverse reaction rate during clinical trials was low, primarily consisting of mild to moderate local reactions that typically resolved quickly, indicating good overall safety [7]. - The vaccine provides protection against nine HPV types associated with cervical cancer, demonstrating comparable immune response levels to existing products in clinical studies published in a reputable medical journal [4][7]. Group 3: Market Impact and Accessibility - The vaccine has received approval from the National Medical Products Administration, supported by robust clinical data on safety and efficacy [9]. - The affordable pricing strategy is expected to enhance accessibility for eligible women, promoting higher vaccination rates and contributing positively to cervical cancer prevention efforts [9].

Core Insights - The launch of China's first domestically developed nine-valent HPV vaccine marks a significant milestone in cervical cancer prevention for women aged 9 to 45 in Beijing, providing a more comprehensive and cost-effective option compared to imported vaccines [1][2] - The vaccine, developed using a novel E. coli expression system, underwent 18 years of research and over one million independent tests, demonstrating safety and efficacy approved by the National Medical Products Administration [1] - The pricing for the vaccine is set at 499 yuan per dose, with a total cost of 998 yuan for a two-dose regimen for females aged 9-17, and 1497 yuan for a three-dose regimen for those aged 18-45 [1] Group 1 - The nine-valent HPV vaccine is the second of its kind globally and aims to break the long-standing monopoly of imported vaccines in the market [1] - Clinical trial data supporting the vaccine's safety and efficacy has been published in The Lancet Infectious Diseases [1] - The vaccine's introduction is expected to strengthen health protection for women in China against cervical cancer and related diseases [1] Group 2 - The vaccination service for the domestic nine-valent HPV vaccine has been fully launched in Beijing, with the first batch delivered to community health service centers across the city [2] - Preparations by local health departments are in place to ensure an orderly vaccination process [2] - Citizens can access information and make appointments for vaccination through the Jingtong mini-program, the Capital Vaccine Service APP, or by contacting local community health service centers [2]

Group 1 - The first domestically produced nine-valent HPV vaccine has been officially launched in Beijing, providing a new and economical option for women aged 9 to 45 in cervical cancer prevention [1] - The vaccine can effectively prevent over 70% of cervical cancer cases and reduce the incidence of other diseases caused by HPV infection [1] - The National Health Commission has included the HPV vaccine in the national immunization program, offering free vaccinations for girls aged 13 who were born after November 10, 2011 [1] Group 2 - The nine-valent HPV vaccine was developed by Xiamen University and Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., taking 18 years to complete [2] - Clinical trials involving over 11,000 healthy volunteers aged 9 to 45 have been conducted since 2019, demonstrating the vaccine's immunogenicity and safety comparable to imported products [2] - The vaccine is priced at 499 yuan per dose, with a total of 3 doses required for women aged 18 to 45, while those aged 9 to 17 only need 2 doses [2]

Group 1 - The core viewpoint of the article highlights the launch of the domestically developed nine-valent HPV vaccine in Beijing, providing a more comprehensive and cost-effective option for cervical cancer prevention for women aged 9 to 45 [1] - This vaccine is the second nine-valent HPV vaccine globally and marks a significant step in breaking the long-standing monopoly of imported vaccines in the market [2]

Group 1 - The Chinese government has decided to include the HPV vaccine in the national immunization program starting from November 10, 2025, targeting girls born after November 10, 2011, who are 13 years old, providing them with two doses of the bivalent HPV vaccine for free [1][2] - The decision is based on the rising incidence and mortality rates of cervical cancer in China, particularly among younger populations, highlighting the importance of HPV vaccination in preventing high-risk HPV infections and reducing the occurrence of cervical cancer [1][2] - The World Health Organization recommends vaccinating girls aged 9 to 14 years before they become sexually active, while China has set the target group for free vaccination at 13 years old, considering the optimal balance of protection effectiveness, cost-effectiveness, and operational feasibility [1][2] Group 2 - The notification emphasizes the need for monitoring the production and supply of HPV vaccines, with various departments responsible for ensuring stable production and addressing challenges faced by manufacturers [2] - China has a total annual production capacity of 55 million doses of the bivalent HPV vaccine from two domestic manufacturers, which is sufficient to meet market demand, and these vaccines have received pre-certification from the World Health Organization [2] - The first domestically produced nine-valent HPV vaccine was approved for market use in mid-2023, marking it as the second nine-valent HPV vaccine globally and breaking the long-standing market monopoly held by foreign products [2]

Core Points - The National Health Commission of China announced that the HPV vaccine will be included in the national immunization program starting November 10, 2025, allowing girls aged 13 and above to receive two doses of the bivalent HPV vaccine for free [1][3] - The decision comes in response to the rising incidence and mortality rates of cervical cancer in China, particularly among younger women, highlighting the importance of HPV vaccination in preventing high-risk HPV infections and related diseases [3][4] - The bivalent HPV vaccine, produced by two domestic manufacturers, Xiamen Wantai and Watson Biotech's Zairun Biotech, has received prequalification from the World Health Organization, confirming its safety and efficacy [3][4] Summary by Sections Vaccination Policy - The notification specifies that only girls born after November 10, 2011, will be eligible for free vaccination, without setting an upper age limit for vaccination [4] - The World Health Organization recommends that the optimal age for HPV vaccination is between 9 and 15 years, which corresponds to the upper grades of elementary school to junior high school in China [4][5] Implementation and Logistics - Local health departments are required to collaborate with education and health authorities to assess the target population and previous vaccination records, ensuring accurate vaccine demand statistics [4] - Training for vaccination personnel will be conducted to prepare for the implementation of the immunization program, including management and monitoring of vaccine usage [4][5] Future Implications - Achieving a 90% vaccination rate among girls is essential for the goal of eliminating cervical cancer, although specific guidelines on vaccination arrangements and targets have yet to be released [5][6] - The inclusion of the HPV vaccine in the national immunization program is seen as a significant step towards reducing cervical cancer cases in the future, with potential long-term public health benefits [6]

Core Viewpoint - The Chinese government has included the HPV vaccine in the national immunization program, offering free vaccinations to girls born after November 10, 2011, starting from November 10, 2025, to combat the rising incidence of cervical cancer [1][2]. Group 1: HPV Vaccine Implementation - The HPV vaccine will be administered free of charge to girls aged 13 years and older, specifically targeting those born after November 10, 2011, with a schedule of two doses spaced six months apart [1]. - The vaccine's safety and efficacy have been validated over years of use in China, and current production capacity can meet the anticipated demand [1]. - Local health authorities are required to assess the number of eligible girls and their previous vaccination status, set up vaccination sites, train staff, and adapt the immunization information system accordingly [1]. Group 2: Cervical Cancer Prevention - Cervical cancer is a common malignancy among women in China, with increasing incidence and mortality rates, particularly among younger women [2]. - The World Health Organization's strategy aims for 90% of girls under 15 to be vaccinated by 2030, aligning with China's recent action plan to accelerate cervical cancer elimination [2]. - Various provinces in China have already implemented policies to provide free or subsidized HPV vaccinations for eligible girls, laying the groundwork for the national program [2].

Core Viewpoint - The inclusion of the HPV vaccine in the national immunization program aims to prevent cervical cancer, which has seen rising incidence and mortality rates in China, particularly among younger populations [2][3]. Group 1: HPV Vaccine Inclusion - The HPV vaccine is recognized as the most economical and effective long-term intervention to reduce the risk of cervical cancer, with the potential to prevent over 70% of cases [2]. - The decision to include the HPV vaccine in the national immunization program is intended to reduce disparities in vaccination rates across different regions and income groups, ensuring equitable access to preventive services [2]. Group 2: Target Population - The target population for the free HPV vaccination is girls aged 13 years and older, specifically those born after November 10, 2011, to maximize the vaccine's protective effects before the onset of sexual activity [3]. - Research indicates that girls aged 9 to 14 years produce more than double the antibody levels compared to those over 15, providing longer-lasting protection [3]. Group 3: Vaccination Procedure - The vaccination process involves administering two doses of the bivalent HPV vaccine, with the second dose given six months after the first, and it is crucial that the interval does not exceed one year [4]. - The HPV vaccine can be administered simultaneously with other vaccines without compromising efficacy or increasing safety risks, provided different injection sites and syringes are used [4]. Group 4: Precautions and Additional Measures - For minors receiving the HPV vaccine, parental or guardian accompaniment is required, along with necessary documentation such as identification and consent forms [5]. - Post-vaccination, individuals should observe the injection site for 30 minutes to monitor for any adverse reactions [5]. - In addition to vaccination, maintaining a healthy lifestyle and regular cervical cancer screenings are essential for effective prevention and control of cervical cancer [6].

Core Insights - The first domestic nine-valent HPV vaccine was administered in Shenzhen, marking China as the second country globally to independently supply high-cost HPV vaccines [1] Group 1: HPV Vaccine Overview - The nine-valent HPV vaccine is approved for women aged 9 to 45, targeting two peak infection age groups: under 25 and 40-44 [3] - The vaccine covers nine types of HPV, including seven high-risk types, and has a pricing structure of 520 yuan per dose, making it more accessible [3] - The vaccination schedule varies by age: two doses for girls aged 9-17 and three doses for women aged 18-45 [3] Group 2: Cervical Cancer Statistics - Cervical cancer is a significant health threat in China, with 151,000 new cases reported in 2022, the highest globally [2] - The incidence of cervical cancer has been rising since 2000, with a trend towards younger age groups, particularly among women under 25 [2] Group 3: Public Health Initiatives - There are initiatives to promote HPV vaccination among schoolgirls, particularly in Guangdong Province, where a free vaccination program is available for first-year middle school girls [4] - The health authorities are conducting public awareness campaigns to educate women about the benefits of vaccination and cervical cancer prevention [4] Group 4: Clinical Efficacy and Safety - Clinical studies indicate that the domestic nine-valent HPV vaccine provides 100% protection against persistent infection from high-risk HPV types [4] - Most observed adverse events are mild to moderate and typically resolve on their own, similar to common reactions from other vaccines [4][5] Group 5: Research and Development - The vaccine was developed by a team from Xiamen University and Wantai Biological Pharmacy, utilizing a novel technology platform that has established a complete system of independent intellectual property rights [5]

Core Viewpoint - The first domestic nine-valent HPV vaccine in China has been administered in Shenzhen, marking a significant step in the country's ability to independently supply high-quality HPV vaccines, making China the second country globally to achieve this milestone [1][6]. Group 1: HPV Vaccine Introduction - The nine-valent HPV vaccine is approved for women aged 9 to 45, targeting two peak infection age groups: under 25 and 40-44 [6]. - The vaccine covers nine types of HPV, including seven high-risk types, and offers a reduced dosage schedule for younger girls, requiring only two doses for those aged 9-17, while women aged 18-45 need three doses [6]. - The price of the vaccine is set at 520 yuan per dose, making it more accessible and affordable for the public [6]. Group 2: Cervical Cancer Statistics and Prevention - Cervical cancer poses a significant health threat to women in China, with 151,000 new cases reported in 2022, the highest globally [5]. - The incidence of cervical cancer in China has been rising since 2000, with a trend towards younger age groups, particularly among women under 25 [5]. - HPV is responsible for 99.7% of cervical cancer cases, and vaccination is recognized as one of the safest and most effective preventive measures [5]. Group 3: Vaccine Development and Technology - The nine-valent HPV vaccine was developed by a team led by Academician Xia Ning Shao from Xiamen University in collaboration with Wantai Biological Pharmacy [7]. - The vaccine utilizes a globally innovative E. coli virus-like particle expression technology platform, overcoming long-standing technical barriers and establishing a complete system of independent intellectual property rights [7]. Group 4: Expert Recommendations - Experts emphasize the importance of vaccination to prevent persistent HPV infections, which are a significant risk factor for cervical cancer [7]. - It is recommended that eligible women, especially girls aged 9-14, should receive the HPV vaccine to protect themselves effectively [6][7].